Skip to main content
SpringerLink
Log in

Agencies review aliskiren after termination of multinational trial

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Novartis.Novartis announces termination of ALTITUDE study with Rasilez(Rm)/ Tekturna(Rm) in high-risk patients with diabetes and renal impairment. Media Release: 20 Dec 2011. Available from: URL: http://www.novartis.com

  2. Rasilez (aliskiren): Health Canada reviewing safety of blood-pressure drug. Media Release: 22 Dec 2011. Available from: URL: http://www.hc-sc.gc.ca

  3. European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study. Media Release: 22 Dec 2011. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agencies review aliskiren after termination of multinational trial. React. Wkly. 1384, 1 (2012). https://doi.org/10.2165/00128415-201213840-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213840-00001

Keywords

Search

Navigation